We use cookies to improve the performance of our site and optimize it for our users. Customize Cookie Preferences

Sign Up Today and Learn More About TauRx Pharmaceuticals Stock

Invest in or calculate the value of your shares in TauRx Pharmaceuticals or other pre-IPO companies through EquityZen's platform.

Get Started

TauRx Pharmaceuticals Stock (TAPH)

TauRx Pharmaceuticals is a life sciences company developing drugs and diagnostics for neurodegenerative diseases.

About TauRx Pharmaceuticals Stock

Founded

2002

Industries

Software, Data and Analytics, Artificial Intelligence

TauRx Therapeutics Ltd was established in Singapore in 2002 with the aim of developing new treatments and diagnostics for a range of neurodegenerative diseases based on an entirely new approach which targets aggregates of abnormal fibres of Tau protein that form inside nerve cells in the brain. The TauRx team have since discovered that LMTX™ could also have beneficial effects in several other neurodegenerative diseases associated with Tau pathology, as well as other protein aggregation disorders including Parkinson’s, Huntington’s and Frontotemporal Dementia (Pick’s Disease). While TauRx headquarters are in Singapore, its primary research facilities are in Aberdeen, Scotland.

TauRx Pharmaceuticals Management

Leadership team at TauRx Pharmaceuticals

Chief Business Officer (Aberdeen)

Tim Earle

Chief Development Officer (Aberdeen)

John K S Cheung

Locked Features

Join now and verify your accreditation status to gain access to:

  • TauRx Pharmaceuticals current valuation
  • TauRx Pharmaceuticals stock price
  • Available deals in TauRx Pharmaceuticals and all other companies
  • Deal offering documents
  • EquityZen's proprietary data and insights, including
    • Cap tables, which include funding history by Share Class and Liquidity Preferences
    • Company Highlights
    • Business Model
    • Risk Factors
Join Now

How to invest in TauRx Pharmaceuticals stock?

Accredited investors can buy pre-IPO stock in companies like TauRx Pharmaceuticals through EquityZen funds. These investments are made available by existing TauRx Pharmaceuticals shareholders who sell their shares on our platform. Typically, these are early employees who need to fund a life event – house, education, etc. Accredited investors are then offered the opportunity to invest in this stock through a fund, like those used by hedge funds serving large investors. While not without risk, investing in private companies can help investors reach goals of portfolio diversification, access to potential growth and high potential return. Learn more about our Guided Investment process here.

How to sell TauRx Pharmaceuticals stock?

Shareholders can sell their TauRx Pharmaceuticals stock through EquityZen's private company marketplace. EquityZen's network includes over 320K accredited investors interested in buying private company stock. Learn more about the easy and guided Shareholder process here.

If I invest, how do I exit my investment?

There are two ways to exit your private company investment on EquityZen's marketplace. The first is if the company has an exit event like an IPO, merger or acquisition. In that case, we will distribute the shares and/or cash to you directly. The second way is through an Express Deal on EquityZen, if eligible. An Express Deal allows you to sell your allocation of private shares in a given private company to another investor on EquityZen's marketplace. More information on Express Deals can be found here and exit information can be found here.

Why choose EquityZen?

Since 2013, the EquityZen marketplace has made it easy to buy and sell shares in private companies. EquityZen brings together investors and shareholders, providing liquidity to early shareholders and private market access to accredited investors. With low investment minimums through our funds and with more than 42K private placements completed across 450+ companies, EquityZen leads the way in delivering "Private Markets for the Public."